Literature DB >> 8395331

Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.

R G Vile1, I R Hart.   

Abstract

We report here the use of the 5' flanking region of the murine tyrosinase gene to direct expression of the herpes simplex virus thymidine kinase (tk) gene specifically to murine melanoma cells, whilst not permitting expression in a range of other cell types. Expression of the herpes simplex virus tk gene from the tyrosinase promoter in melanoma cells rendered them sensitive to killing by ganciclovir (100% cell death of a tk-expressing B16 clone after 12 days in culture at 1 microgram/ml ganciclovir). We also observed a substantial bystander killing effect when expressing cells were mixed with nontransfected parental B16 cells. When transfected murine melanoma cells expressing tk were injected into syngeneic mice both their tumorigenicity and experimental metastatic potential were abrogated completely when the mice were treated with ganciclovir (27 of 28 mice treated with water developed progressively growing tumors versus 1 of 30 in the ganciclovir-treated group). Direct injection of the tk gene under control of the tyrosinase promoter into established tumors in mice, followed by treatment with ganciclovir, led to significant reductions in resultant tumor size relative to the size of tumor developing in mice treated with water (median tumor weight, 1.65 g versus 2.75 g). Therefore, direct transfer of recombinant genes by injection of DNA can significantly reduce established tumor burden in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395331

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Bart De Geest; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

Review 2.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 3.  Development of retroviral vectors as safe, targeted gene delivery systems.

Authors:  W H Günzburg; B Salmons
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

4.  Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Authors:  R M Diaz; T Eisen; I R Hart; R G Vile
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 5.  New therapeutic approaches based on gene transfer techniques.

Authors:  H Chong; R G Vile
Journal:  Springer Semin Immunopathol       Date:  1996

Review 6.  Direct cell killing by suicide genes.

Authors:  L A Martin; N R Lemoine
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 7.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

8.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

Authors:  J Fick; F G Barker; P Dazin; E M Westphale; E C Beyer; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 9.  Genes, dreams, and cancer.

Authors:  K Sikora
Journal:  BMJ       Date:  1994-05-07

10.  Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Authors:  E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher
Journal:  Gene Ther       Date:  2009-03-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.